Resistance to Critical Important Antibacterials in Staphylococcus pseudintermedius Strains of Veterinary Origin

Abstract

Staphylococcal infections represent a challenge in companion animals and hospitalized patients. This study aimed to assess the resistance of Staphylococcus pseudintermedius isolates, against a broad panel of antibacterials, including exclusive to human medicine. A total of 40 S. pseudintermedius were collected from clinical specimens of dogs (n = 31) and cats (n = 5). All strains were tested for 20 antibacterials, namely 14 Critical Important and eight Highly Important Antibacterials (CIA and HIA, respectively), indicative for 18 antimicrobial classes. All strains were susceptible to seven antibiotics (daptomycin, fosfomycin, fusidic acid, linezolid, quinupristin-dalfopristin, teicoplanin/vancomycin, tigecycline). The highest resistance was against penicillin (97.5% Confidence Interval [CI]: 83.8–100.0), whereas the lowest against telavancin (2.5%, CI: 0.0–16.2). Resistance versus Highest Priority CIA was observed, namely against macrolides (70.0, CI: 52.1–84.3), quinolones (62.5, CI: 44.5–78.3), 5th generation cephalosporins (7.5, CI: 1.3–21.6), and glycopeptides (2.5%, CI: 0.0–14.2). Among High Priority CIA, strains were resistant only to aminoglycosides (65.0, CI: 47.0–80.4) and ansamycins (12.5, CI: 3.8–28.1). We observed the highest resistance against veterinary medicine antibacterials, but there was also resistance against antibacterials exclusive to human medicine, namely ceftaroline (7.5, CI: 1.0–23.8) and telavancin. S. pseudintermedius zoonotic potential and its rate of acquisition of new resistance should encourage surveillance on a broad spectrum of antibacterials.

In vitro activity of selected antimicrobials against methicillin‐resistant Staphylococcus pseudintermedius of canine origin in Poland

“…When it comes to vancomycin, linezolid and mupirocin, despite the use of recommendations for staphylococci strains of human origin, the obtained inhibition zone diameters and MIC values were suggestive of a wild‐type population with full susceptibility. These results are consistent with the literature data (Bellato et al., 2022 ; Kasai et al., 2016 ; Wegener et al., 2018 ). However, previous reports describing uncommon cases of mupirocin resistance indicate a possibility of acquiring resistance if its genetic determinants become disseminated within the MRSP population (Kizerwetter‐Świda et al., 2021 ).…”

Multidrug-Resistant Commensal and Infection-Causing Staphylococcus spp. Isolated from Companion Animals in the Valencia Region

“…pseudintermedius isolated from dogs were resistant to RIF, while all cat strains were susceptible [ 69 ]. The same has been reported for DAP by Bellato et al (2022) but with a higher AMR to RIF (12.5%) [ 82 ].…”

“…This high acquired AMR for this antibiotic represents a major public health concern, as it is one of the newest last resort antibiotics used to treat MDR infections caused by Staphylococcus strains [ 79 , 80 ]. On the other hand, all cat isolates were susceptible to tigecycline, as reported in other studies in isolates from cats and other animal species [ 81 , 82 , 83 ], as well as humans [ 83 , 84 ].…”

“…Different AMR rates have been observed in companion animals [93,94], as reported by Burke et al (2023) in a 10-year study, where only one S. schleiferi and one S. pseudintermedius isolated from dogs were resistant to RIF, while all cat strains were susceptible [69]. The same has been reported for DAP by Bellato et al (2022) but with a higher AMR to RIF (12.5%) [82].…”

Genetic diversity and antimicrobial resistance profiles of Staphylococcus pseudintermedius associated with skin and soft-tissue infections in companion animals in Lisbon, Portugal

“…Although that earlier work included S. pseudintermedius causing pyoderma and other infections (mostly otitis and urinary tract infections), comparison between the two studies highlights a nearly three-fold increase in resistance frequency rate for fluoroquinolones (9.2% vs. 25.2%), and nearly a two-fold increase for trimethoprim-sulfamethoxazole (16.4% vs. 30.3%), aminoglycosides (23.3% vs. 41.9%) and clindamycin (20.6% vs. 36.8%). Although in a lesser extent, increase in resistance to penicillin (64.4% vs. 85.2%) and tetracyclines (44.0% vs. 55.5%) is also relevant, as reported for other European countries ( Haenni et al, 2020 ), including Spain ( Ruiz-Ripa et al, 2021 ; Viñes et al, 2022 ), and Italy ( Bellato et al, 2022 ). Resistance to fusidic acid (4.5%) followed the same increasing trend when compared to previous data from Portugal [0.9% ( Couto et al, 2016 ) or 3.2% ( Silva et al, 2021 )].…”